



# Press Release

## **FUSE-AI takes off**

*Global distribution launched at the G20 Digital Innovation Network*

Hamburg, 12<sup>th</sup> September, 2022. The G20 Digital Innovation Network is a high-level forum for sharing knowledge, fostering discussion, and building partnerships between global innovation players. It aims to serve as a bridge for cooperation between different players at the global level.

For the last meeting in Bali at the beginning of September, the Federal Ministry of Digital Affairs and Transport (BMDV) nominated five German start-ups, including the Hamburg-based AI experts from FUSE-AI. This gave Dr Sabrina Reimers-Kipping, Head of Medical and Scientific Affairs, and Juri Rohde, Head of Regulatory & Operations, the opportunity to represent Germany as the only delegates from the health industry.

### **A solution that inspired**

The two brought the AI-based assistance software Prostate.Carcinoma.ai with them to Indonesia. "The software provides reliable and reproducible segmentation of the prostate, prostate zones and suspicious lesions. It determines exact prostate and lesion volumes as well as region-of-interest (ROI) coordinates," Dr Reimers-Kipping explains the software. It can be seamlessly integrated into all image data management and diagnostic systems. The ISO 13458 and MDSAP certified plug-in solution will be routinely available to users from the beginning of 2023.

Prostate.Carcinoma.ai also convinced the jury in Indonesia. "They were enthusiastic about the technology, the positioning and the market fit of our AI software," says Rohde. FUSE-AI used this praise as the starting signal for international sales in Southeast Asia. "We had the great opportunity to present ourselves to the key innovation players and policy makers of the G20 countries on a global stage and established new and interesting contacts with investors and relevant companies. This lays the foundation for a successful market entry," Dr. Sabrina Reimers-Kipping is pleased to report.

Text size: 1,915 characters incl spaces

### **About FUSE-AI**

FUSE-AI has two main focuses: Medicine and IT. The guiding principle is to offer physicians a second opinion in diagnosis via the use of artificial intelligence in order to increase the medical standard of physician performance.

In addition, AI is widely applicable in numerous further disciplines. These include, for example, drug discovery, biomarker development, intelligent image recognition, genome analysis, as well as morphometric imaging in digital pathology, therapy support systems with healing prognosis, mobile apps for intelligent collection of vital data.

The team of FUSE-AI works interdisciplinary and is represented by biochemists, biologists, physicians as well as IT developers and machine learning experts. Together, they design new



# Press Release

approaches for optimizing processes in healthcare, strictly in accordance with German data protection guidelines.

Further information about FUSE-AI: [www.fuse-ai.de](http://www.fuse-ai.de)

Further information about prostate.carcinoma.ai: [prostate.carcinoma.ai](http://prostate.carcinoma.ai).

Press contact  
FUSE-AI  
Anne Wesche  
Großer Burstah 46/48  
20457 Hamburg  
Telefon: +49 (0)40 4503180  
E-Mail: [anne.wesche@fuse-ai.de](mailto:anne.wesche@fuse-ai.de)